Anne Pollak - DBV Technologies Head Relations
| DBVT Stock | USD 4.25 0.28 7.05% |
Insider
Anne Pollak is Head Relations of DBV Technologies
| Address | 177-181 Avenue Pierre Brossolette, Montrouge, France, 92120 |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
DBV Technologies Management Efficiency
The company has return on total asset (ROA) of (0.4625) % which means that it has lost $0.4625 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0311) %, meaning that it created substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.39 in 2024. Return On Capital Employed is likely to drop to -0.61 in 2024. At this time, DBV Technologies' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 3.3 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 31 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Thomas Templeman | Centessa Pharmaceuticals PLC | 64 | |
| Pascal Caisey | Genfit | 55 | |
| Michael Gerometta | Opthea | 59 | |
| Mark Lappe | Inhibrx | 57 | |
| Annie Lee | Opthea | N/A | |
| Seshadri Neervannan | Tarsus Pharmaceuticals | 56 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| David Chao | Centessa Pharmaceuticals PLC | 56 | |
| Mondher MD | Innate Pharma | 66 | |
| MD MBA | Opthea | N/A | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| Prof Shair | Nuvalent | 55 | |
| Leonard JD | Tarsus Pharmaceuticals | 48 | |
| Vicky Hahne | Celcuity LLC | 58 | |
| Yannis Morel | Innate Pharma | 51 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| Dr Roberts | Lyra Therapeutics | 56 | |
| MD MBA | Rezolute | N/A | |
| Odile Belzunce | Innate Pharma | 44 | |
| MBA MD | Ikena Oncology | 59 | |
| Matthew Gall | Iteos Therapeutics | 47 | |
Management Performance
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.46 |
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Becker, VP Communications | ||
| Sbastien Robitaille, Chief Officer | ||
| Wence Agbotounou, Chief Clinical Trial Officer | ||
| Caroline Daniere, Chief Staff | ||
| Daniel Tass, CEO Director | ||
| Edward MBA, Senior America | ||
| Alan Kerr, Senior Affairs | ||
| Pascal Wotling, Chief Officer | ||
| Pharis Mohideen, Chief Officer | ||
| Virginie MBA, CFO Officer | ||
| Katie Matthews, Investor Officer | ||
| Lucie Mondoulet, Director of Research Department | ||
| Anne Pollak, Head Relations | ||
| Michele Robertson, Chief Officer |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (28.29) % | ||||
| Current Valuation | 36.63 M | ||||
| Shares Outstanding | 19.24 M | ||||
| Shares Owned By Institutions | 16.70 % | ||||
| Number Of Shares Shorted | 1.26 M | ||||
| Price To Earning | (8.25) X | ||||
| Price To Book | 1.51 X | ||||
| Price To Sales | 6.53 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for DBV Stock Analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.